US4186211A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Higher alkanol compositions and the use thereof in treatment of prostate disorders
Assignee: Institut de Recherches Chimiques et Biologiques Appliquees SARL IRCEBA
•
Filing: 1974-08-30
•
Granted: 1980-01-29
•
Expires: 1994-08-30
Abstract
Abstract This invention is concerned with a therapeutic composition intended in particular for the treatment of secretory disorders of the prostate gland, containing a pharmaceutically active quantity of at least one higher alkanol with 16 or more carbon atoms or one of its esters in association with a physiologically acceptable vehicle.
Inventors
- 👤 Jacques Debat
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 17:44
CPC Classifications
C; C07; C07C; C07C29/00; C07C29/132; C07C29/136; C07C29/147; A; A61; A61K; A61K31/00; A61K31/045; C07C29/36; C07C29/38; C07C29/40
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
42 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 1-docosanol, 13-cis-docosen-1-ol, 9-cis, 12-cis-octadecadien-1-ol, or 2-eicosanol in association with a physiologically acceptable vehicle.
Claim 2
Independent Claim
42 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 1-docosanol, 13-cis-docosen-1-ol, 9-cis, 12-cis-octadecadien-1-ol, or 2-eicosanol in association with a physiologically acceptable vehicle.
Claim 3
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment of composition containing a therapeutically effective amount of 1-docosanol in association with a physiologically acceptable vehicle.
Claim 4
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment of composition containing a therapeutically effective amount of 1-docosanol in association with a physiologically acceptable vehicle.
Claim 5
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 13-cis-docosen-1-ol in association with a physiologically acceptable vehicle.
Claim 6
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 13-cis-docosen-1-ol in association with a physiologically acceptable vehicle.
Claim 7
Independent Claim
38 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 9-cis, 12-cis-octadecadien-1-ol in association with a physiologically acceptable vehicle.
Claim 8
Independent Claim
38 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 9-cis, 12-cis-octadecadien-1-ol in association with a physiologically acceptable vehicle.
Claim 9
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 2-eicosanol in association with a physiologically acceptable vehicle.
Claim 10
Independent Claim
37 words
The method of treatment of enlargement of the prostate gland which comprises administering to a patient in need of said treatment a composition containing a therapeutically effective amount of 2-eicosanol in association with a physiologically acceptable vehicle.
Claim 11
Dependent Claim
21 words
The method according to claim 2 wherein the amount of 1-docosanol is 0.5 mg. per kg. of body weight per day.
Claim 12
Dependent Claim
83 words
A pharmaceutical composition for the treatment of the enlargement of the prostate gland containing as the only active ingredient 1-docosanol, 13-cis-docosen-1-ol, 9-cis, 12-cis-octadecadien-1-ol or 2-eicosanol in the amount of 1-90% by weight of the composition in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 13
Dependent Claim
83 words
A pharmaceutical composition for the treatment of the enlargement of the prostate gland containing as the only active ingredient 1-docosanol, 13-cis-docosen-1-ol, 9-cis, 12-cis-octadecadien-1-ol or 2-eicosanol in the amount of 1-90% by weight of the composition in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 14
Dependent Claim
63 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective amount of 1-docosanol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carobxymethyl cellulose, a low melting eas, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 15
Dependent Claim
63 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective amount of 1-docosanol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carobxymethyl cellulose, a low melting eas, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 16
Dependent Claim
63 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective amount of 13-cis-docosen-1-ol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 17
Dependent Claim
63 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective amount of 13-cis-docosen-1-ol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 18
Dependent Claim
65 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective of amount of 9-cis, 12-cis-octadecadien-1-ol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 19
Dependent Claim
65 words
A pharmaceutical composition containing as the sole active ingredient a therapeutically effective of amount of 9-cis, 12-cis-octadecadien-1-ol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 20
Dependent Claim
63 words
A pharmaceutically composition containing as the sole active ingredient a therapeutical effective amount of 2-eicosanol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
Claim 21
Dependent Claim
63 words
A pharmaceutically composition containing as the sole active ingredient a therapeutical effective amount of 2-eicosanol, in association with a physiologically acceptable vehicle, which is selected from the group consisting of magnesium carbonate, magnesium stearate, talcum, saccharose, glucose, lactose, pectin, dextrin, starch, gelatin, tragacanth, gum arabic, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, polyethylene glycol, polypropylene glycol and olive oil.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-01-28 | 1983-07-30 | 1984-01-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-01-28 | 1987-07-30 | 1988-01-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-01-28 | 1991-07-30 | 1992-01-29 | $7700.00 | Window Closed / Lapsed |